Statins reduce melanoma development and metastasis through MICA overexpression

Frontiers in Immunology

Volumn 4, Issue MAR, 2013, Pages

  Pich, Christine ^a,b,c   Teiti, Iotefa ^a,b,c   Rochaix, Philippe ^b   Mariamé, Bernard ^c,d   Couderc, Bettina ^b,c,e   Favre, Gilles ^a,b,c   Tilkin Mariamé, Anne Françoise ^a,b,c  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d University of Toulouse III   (France)

^e EA 4553   (France)

Author keywords

Melanoma; MICA; NK cells; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NATURAL KILLER CELL RECEPTOR NKG2D; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEOME; RAS PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MELANOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84882995882     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00062     Document Type: Article

References (32)

1. Balakumar, P., and Mahadevan, N. (2012). Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br. J. Pharmacol. 165, 373-379.
2. Berman, D., Parker, S. M., Siegel, J., Chasalow, S. D., Weber, J., Galbraith, S., et al. (2010). Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 10, 11.
3. Boudreau, D. M., Yu, O., and Johnson, J. (2010). Statin use and cancer risk: a comprehensive review. Expert Opin. Drug. Saf. 9, 603-621.
4. Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
5. Cerwenka, A., and Lanier, L. L. (2001). Ligands for natural killer cell receptors: redundancy or specificity. Immunol. Rev. 181, 158-169.
6. Chavez-Blanco, A., De la Cruz-Hernandez, E., Dominguez, G. I., Rodriguez-Cortez, O., Alatorre, B., Perez-Cardenas, E., et al. (2011). Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. Int. J. Oncol. 39, 1491-1499.
7. Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
8. Fuertes, M. B., Girart, M. V., Molinero, L. L., Domaica, C. I., Rossi, L. E., Barrio, M. M., et al. (2008). Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity. J. Immunol. 180, 4606-4614.
9. Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., et al. (2008). NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571-580.
10. He, T., Xue, Z., Lu, K. M., Valdivia, Y. A. M., Wong, K. K., Xie, W., et al. (2012). A minimally invasive multimodality image-guided (MIMIG) system for peripheral lung cancer intervention and diagnosis. Comput. Med. Imaging Graph 36, 345-355.
11. Heasman, S. J., and Ridley, A. J. (2008). Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 9, 690-701.
12. Heinaniemi, M., Uski, J. O., Degenhardt, T., and Carlberg, C. (2007). Meta-analysis of primary target genes of peroxisome proliferator-activated receptors. Genome Biol. 8, R147.
13. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R.W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
14. Holmen, C., Elsheikh, E., Christensson, M., Liu, J., Johansson, A. S., Qureshi, A. R., et al. (2007). Anti endothelial cell autoantibodies selectively activate SAPK/JNK signalling in Wegener's granulomatosis. J. Am. Soc. Nephrol. 18, 2497-2508.
15. Jacobs, E. J., Newton, C. C., Thun, M. J., and Gapstur, S. M. (2011). Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 71, 1763-1771.
16. Kimura, R. H., Cheng, Z., Gambhir, S. S., and Cochran, J. R. (2009). Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res. 69, 2435-2442.
17. Lanier, L. L. (2008). Up on the tightrope: natural killer cell activation and inhibition. Nat. Immunol. 9, 495-502.
18. Mehlen, P., and Puisieux, A. (2006). Metastasis: a question of life or death. Nat. Rev. Cancer 6, 449-458.
19. Mery, E., Jouve, E., Guillermet, S., Bourgognon, M., Castells, M., Golzio, M., et al. (2011). Intraoperative fluorescence imaging of peritoneal dissemination of ovarian carcinomas. A preclinical study. Gynecol. Oncol. 122, 155-162.
20. Meyer, S., Vogt, T., Landthaler, M., Berand, A., Reichle, A., Bataille, F., et al. (2009). Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res. 2009, 848645.
21. Peters, J. M., Shah, Y. M., and Gonzalez, F. J. (2012). The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat. Rev. Cancer 12, 181-195.
22. Rauwel, B., Mariame, B., Martin, H., Nielsen, R., Allart, S., Pipy, B., et al. (2010). Activation of peroxisome proliferator-activated receptor gamma by human cytomegalovirus for de novo replication impairs migration and invasiveness of cytotrophoblasts from early placentas. J. Virol. 84, 2946-2954.
23. Rikitake, Y., and Hirata, K. (2009). Inhibition of RhoA or Rac1? Mechanism of cholesterol-independent beneficial effects of statins. Circ. J. 73, 231-232.
24. Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526.
25. Sarrabayrouse, G., Pich, C., Moriez, R., Armand-Labit, V., Rochaix, P., Favre, G., et al. (2010). Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells. PLoS ONE 5:e9043. doi:10.1371/journal.pone.0009043
26. Sarrabayrouse, G, Synaeve, C., Leveque, K., Favre, G., and Tilkin-Mariame, A. F. (2007). Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells. Neoplasia 9, 1078-1090.
27. Sharma, S., Sun, X., Rafikov, R., Kumar, S., Hou, Y., Oishi, P. E., et al. (2012). PPAR-gamma regulates carnitine homeostasis and mitochondrial function in a lamb model of increased pulmonary blood flow. PLoS ONE 7:e41555. doi:10.1371/journal.pone.0041555
28. Szatmari, I, Torocsik, D., Agostini, M., Nagy, T., Gurnell, M., Barta, E., et al. (2007). PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110, 3271-3280.
29. Tilkin-Mariame, A. F., Cormary, C., Ferro, N., Sarrabayrouse, G., Lajoie-Mazenc, I., Faye, J. C., et al. (2005). Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression. FASEB J. 19, 1513-1515.
30. Valdivia, Y. A. M., Wong, K., He, T. C., Xue, Z., and Wong, S. T. (2012). Image-guided fiberoptic molecular imaging in a VX2 rabbit lung tumor model. J. Vasc. Interv. Radiol. 22, 1758-1764.
31. Weeraratna, A. T. (2012). RAF around the edges - the paradox of BRAF inhibitors. N. Engl. J. Med. 366, 271-273.
32. Zhang, C., Wang, Y., Zhou, Z., Zhang, J., and Tian, Z. (2009). Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol. Immunother. 58, 1275-1285.